NCM · —
BNGO (BNGO) Stock
$1.07
+0.94%
NCM: BNGO
—
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Nabsys Appoints Genome Mapping Pioneer Alka Chaubey, Ph.D., as Chief Medical and Genomics Officer
PR Newswire · Jul 6, 2026
Bionano Announces Hiring of Chief Scientific Officer
GlobeNewswire · Jun 24, 2026
Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
GlobeNewswire · Jun 18, 2026
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
GlobeNewswire · Jun 11, 2026
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · Jun 8, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held7.41%
Institutions Held10.12%
Institutions Float Held10.93%
Peer Comparison
About BNGO
BNGO is led by CEO Robert Erik Holmlin, employs 98 people, headquartered in US, publicly traded since 2018.
BNGO stock trades at $1.07 with a market capitalization of $12.28M. The stock is valued at a price-to-earnings (P/E) ratio of -1.16, price-to-book of 0.31, price-to-sales of 0.50. Over the past 52 weeks the stock has ranged between $1.06 and $5.50, and currently trades 80.5% below its 52-week high.
On profitability, BNGO generates a return on equity (ROE) of -66.15%, return on capital employed of -73.33%, an operating margin of -107.36%, a net profit margin of -92.59%.